Comparison of TNF-α levels before and after treatment in patients with periodontitis with and without type 2 diabetes mellitus
Keywords:
Periodontitis, TNF-α, Laser, salivary, diabetes mellitusAbstract
Background: Periodontitis is an inflammatory reaction triggered by the pathogenic microorganisms present in a chronic dental biofilm, which leads to progressive harm to the structures that support teeth. The present study was conducted to compare TNF-α levels before and after treatment in patients with periodontitis with and without type 2 diabetes mellitus.
Materials & Methods:80 patients were divided into 2 groups of 40 each. Group I were periodontitis and group II were periodontitis+ type 2 diabetes mellitus patients. Group I were further subdivided into group A who underwent scaling and root planing alone and group B who underwent scaling and root planing+ low level laser therapy. Group II were further subdivided into group C who underwent scaling and root planing alone and group D who underwent scaling and root planing+ low level laser therapy. In both groups, saliva was collected in a test tube for the assessment of TNF-α levels at baseline and at 8 weeks.
Results: Group A had 1 male and 9 females, group B had 10 males and 10 females, group C had 8 males and 12 females and group D had 9 males and 11 females. The mean age was 45.2±5.2 years, 47.4±5.8years, 46.3±5.1 years and 45.8±3.8 years in group A, B, C and D respectively. The mean BMI was 24.2±3.6 Kg/m2, 23.2±4.1 Kg/m2, 23.1±4.3 Kg/m2 and 22.5±6.1 Kg/m2 in group A, B, C and D respectively. At baseline and 8 weeks, in group A, PI was 1.71, 0.67, BI was 1.92 and 0.48, PD was 6.2 and 2.9 and CAL was 6.5 and 2.5 respectively. In group B, PI was 1.72 and 0.68, BI was 2.1 and 1.4, PD was 5.4 and 2.9 and CAL was 2.8 and 2.7 respectively. In group C, PI was 2.1 and 0.37, BI was 1.94 and 0.41, PD was 5.8and 3.2 and CAL was 6.1 and 3.1 respectively. In group D, PI was 2.1 and 0.4, BI was 1.7 and 0.42, PD was 5.7 and 2.7 and CAL was 5.8 and 2.6 respectively. The difference was significant (P< 0.05). TNF- α at baseline and at 8 weeks in group A was 14.2 ±2.3 and 9.1±1.1, in group B was 14.9±5.3 and 10.5±4.2, in group C was 22.3±7.1 and 14.8±7.2 and in group D was 22.1±8.4 and 12.4±3.1 respectively. The difference was significant (P< 0.05).
Conclusion: Salivary TNF-α levels in periodontitis are associated with T2DM. There was a notable improvement in both clinical and salivary TNF-α levels with SRP and SRP adjunct to LLLT.
Downloads
Metrics
References
Mesia R, Gholami F, Huang H, Clare-Salzler M, Aukhil I, Wallet SM, et al. Systemic inflammatory responses in patients with type 2 diabetes with chronic periodontitis. BMJ Open Diabetes Res Care. 2016;4:e000260.
Shaju JP, Zade RM, Das M. Prevalence of periodontitis in the Indian population: A literature review. J Indian Soc Periodontol. 2011;15:29–34.
Nelson RG, Shlossman M, Budding LM, Pettitt DJ, Saad MF, Genco RJ, et al. Periodontal disease and NIDDM in Pima Indians. Diabetes Care. 1990;13:836–40.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.
Jepsen K, Jepsen S. Antibiotics/antimicrobials: Systemic and local administration in the therapy of mild to moderately advanced periodontitis. Periodontol 2000. 2016;71:82–112.
Prietto NR, Martins TM, Santinoni CD, Pola NM, Ervolino E, Bielemann AM, et al. Treatment of experimental periodontitis with chlorhexidine as adjuvant to scaling and root planing. Arch Oral Biol. 2020;110:104600.
Southerland JH, Taylor GW, Moss K, Beck JD, Offenbacher S. Commonality in chronic inflammatory diseases: Periodontitis, diabetes, and coronary artery disease. Periodontol 2000. 2006;40:130–43.
Yamazaki K, Honda T, Oda T, Ueki-Maruyama K, Nakajima T, Yoshie H, et al. Effect of periodontal treatment on the C-reactive protein and proinflammatory cytokine levels in Japanese periodontitis patients. J Periodontal Res. 2005;40:53–8.
Chen L, Luo G, Xuan D, Wei B, Liu F, Li J, et al. Effects of non-surgical periodontal treatment on clinical response, serum inflammatory parameters, and metabolic control in patients with type 2 diabetes: A randomized study. J Periodontol. 2012;83:435–43.
Correa FO, Gonçalves D, Figueredo CM, Bastos AS, Gustafsson A, Orrico SR. Effect of periodontal treatment on metabolic control, systemic inflammation and cytokines in patients with type 2 diabetes. J Clin Periodontol. 2010;37:53–8.
Pulivarthi P, Chava VK, Gunupati S. Salivary tumor necrosis factor-alpha levels in periodontitis associated with diabetes mellitus after low level laser therapy as an adjunct to scaling and root planning: A randomized clinical trial. Journal of Indian Society of Periodontology. 2022 May 1;26(3):236-44.
Calderín S, García-Núñez JA, Gómez C. Short-term clinical and osteoimmunological effects of scaling and root planing complemented by simple or repeated laser phototherapy in chronic periodontitis. Lasers Med Sci. 2013;28:157–66.
Giannopoulou C, Cappuyns I, Cancela J, Cionca N, Mombelli A. Effect of photodynamic therapy, diode laser, and deep scaling on cytokine and acute-phase protein levels in gingival crevicular fluid of residual periodontal pockets. J Periodontol. 2012;83:1018–27.
Badersten A, Nilvéus R, Egelberg J. Effect of nonsurgical periodontal therapy. I. Moderately advanced periodontitis. J Clin Periodontol. 1981;8:57–72. doi: 10.1111/j.1600-051x.1981.tb02024.x.
Dag A, Firat ET, Arikan S, Kadiroglu AK, Kaplan A. The effect of periodontal therapy on serum TNF-alpha and HbA1c levels in type 2 diabetic patients. Aust Dent J. 2009;54:17–22.
..
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
